Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: sertraline 50 mg daily Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress & Premenstrual Symptoms Study

NCT02777372
View directory record Official record
Conditions
PMDD, Stress, Mood
Interventions
Sertraline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

NCT02891278
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Phase 4 Interventional Results available

Postpartum Depression: Transdermal Estradiol Versus Sertraline

NCT00744328
View directory record Official record
Conditions
Postpartum Depression
Interventions
Transdermal Estradiol, Sertraline, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Riluzole Augmentation Pilot in Depression (RAPID) Trial

NCT01703039
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Riluzole, Sertraline, placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

NCT01250873
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Phase 4 Interventional Results available

Predicting SSRI Efficacy in Veterans With PTSD

NCT04183205
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
LDAEP, Placebo, sertraline
Diagnostic Test · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Not applicable Interventional Results available

Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression

NCT02235064
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder

NCT00048854
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Sertraline, Treatment as usual (TAU)
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

NCT00386243
View directory record Official record
Conditions
Low Back Pain, Pain, Pain, Intractable
Interventions
Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease

NCT00208117
View directory record Official record
Conditions
Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions
Sertraline (Zoloft), Simvastatin (Zocor)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression

NCT00602355
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Sertraline, Placebo, Interpersonal psychotherapy (IPT), Clinical management, Mothercrafting
Drug · Behavioral
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Iowa City, Iowa • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 28, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety

NCT05683223
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Group CBT for Social Anxiety Disorder, Sertraline, Individual CBT for Social Anxiety Disorder
Behavioral · Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 4 Interventional Results available

Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly

NCT00701675
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
sertraline 50 mg daily, sertraline 100 mg daily, Placebo 50 or 100 mg
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Tuscaloosa, Alabama • Miami, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Placebo, BupropionXL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Rhodiola Rosea Therapy of Major Depressive Disorder

NCT01098318
View directory record Official record
Conditions
Depression
Interventions
Herbal extract, Sertraline, Lactose monohydrate
Dietary Supplement · Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 28, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 for Depression and Other Cardiac Risk Factors - 2

NCT02021669
View directory record Official record
Conditions
Depression
Interventions
Omega-3 supplement, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 28, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

NCT01977729
View directory record Official record
Conditions
Anxiety Disorder of Adolescence
Interventions
Sertraline, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
8 Years to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 9:02 PM EDT